Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 30, 2014, Pages 11121-11126

  Santagata, Sandro ^a,b,c   Eberlin, Livia S ^d   Norton, Isaiah ^a   Calligaris, David ^a   Feldman, Daniel R ^a   Ide, Jennifer L ^a   Liu, Xiaohui ^a   Wiley, Joshua S ^d   Vestal, Matthew L ^a   Ramkissoon, Shakti H ^a,b   Orringer, Daniel A ^a   Gill, Kristen K ^a   Dunn, Ian F ^a   Dias Santagata, Dora ^e   Ligon, Keith L ^a,b,c   Jolesz, Ferenc A ^a   Golby, Alexandra J ^a   Cooks, R Graham ^d   Agar, Nathalie Y R ^a,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d PURDUE UNIVERSITY   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Brain cancer; IDH1; Intrasurgical diagnosis; Mass spectrometry imaging; Oncometabolite

Indexed keywords

2 HYDROXYGLUTARIC ACID; ISOCITRATE DEHYDROGENASE 1;

ARTICLE; ASTROCYTOMA; BRAIN SURGERY; BRAIN TUMOR; CANCER PROGNOSIS; CANCER SURGERY; CANCER TISSUE; CLINICAL DECISION MAKING; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; GENE MUTATION; GLIOMA; HUMAN; HUMAN TISSUE; IMAGE RECONSTRUCTION; INTRAOPERATIVE PERIOD; MASS SPECTROMETER; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; OPERATING ROOM; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; THREE DIMENSIONAL IMAGING; TISSUE LEVEL;

BRAIN CANCER; IDH1; INTRASURGICAL DIAGNOSIS; MASS SPECTROMETRY IMAGING; ONCOMETABOLITE;

BRAIN NEOPLASMS; FEMALE; GLIOMA; GLUTARATES; HUMANS; INTRAOPERATIVE CARE; MAGNETIC RESONANCE IMAGING; MALE; MASS SPECTROMETRY;

EID: 84905017731     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1404724111     Document Type: Article

References (54)

1. Cornett DS, Reyzer ML, Chaurand P, Caprioli RM (2007) MALDI imaging mass spectrometry: Molecular snapshots of biochemical systems. Nat Methods 4(10):828-833. (Pubitemid 350055580)
2. Harris GA, Galhena AS, Fernández FM (2011) Ambient sampling/ionization mass spectrometry: Applications and current trends. Anal Chem 83(12):4508-4538.
3. Eberlin LS, et al. (2012) Classifying human brain tumors by lipid imaging with mass spectrometry. Cancer Res 72(3):645-654.
4. Eberlin LS, et al. (2013) Ambient mass spectrometry for the intraoperative molecular diagnosis of human brain tumors. Proc Natl Acad Sci USA 110(5):1611-1616.
5. Eberlin LS, et al. (2014) Molecular assessment of surgical-resection margins of gastric cancer by mass-spectrometric imaging. Proc Natl Acad Sci USA 111(7):2436-2441.
6. Calligaris D, et al. (2013) Mass spectrometry imaging as a tool for surgical decision-making. J Mass Spectrom 48(11):1178-1187.
7. Wiseman JM, Ifa DR, Venter A, Cooks RG (2008) Ambient molecular imaging by desorption electrospray ionization mass spectrometry. Nat Protoc 3(3):517-524. (Pubitemid 351372236)
8. Takáts Z, Wiseman JM, Gologan B, Cooks RG (2004) Mass spectrometry sampling under ambient conditions with desorption electrospray ionization. Science 306(5695):471-473. (Pubitemid 39372443)
9. Agar NY, et al. (2011) Development of stereotactic mass spectrometry for brain tumor surgery. Neurosurgery 68(2):280-289, discussion 290.
10. Parsons DW, et al. (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321(5897):1807-1812.
11. Losman JA, Kaelin WG, Jr (2013) What a difference a hydroxyl makes: Mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev 27(8):836-852.
12. Borger DR, et al. (2012) Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist 17(1):72-79.
13. Mardis ER, et al. (2009) Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361(11):1058-1066.
14. Amary MF, et al. (2011) IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol 224(3):334-343.
15. Dang L, et al. (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462(7274):739-744.
16. Lu C, et al. (2012) IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483(7390):474-478.
17. Turcan S, et al. (2012) IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483(7390):479-483.
18. Xu W, et al. (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 19(1):17-30.
19. Koivunen P, et al. (2012) Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 483(7390):484-488.
20. Wang F, et al. (2013) Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 340(6132):622-626.
21. Rohle D, et al. (2013) An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340(6132):626- 630.
22. Losman JA, et al. (2013) (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 339(6127):1621-1625.
23. Andronesi OC, et al. (2012) Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med 4(116):ra4.
24. Choi C, et al. (2012) 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 18(4):624-629.
25. Elkhaled A, et al. (2012) Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas. Sci Transl Med 4(116):ra5.
26. Pope WB, et al. (2012) Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neurooncol 107(1):197-205.
27. Andronesi OC, et al. (2013) Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate. J Clin Invest 123(9):3659-3663.
28. Sanai N, Berger MS (2008) Glioma extent of resection and its impact on patient outcome. Neurosurgery 62(4):753-764, discussion 264-266.
29. Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS (2011) An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 115(1):3-8.
30. Smith JS, et al. (2008) Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 26(8):1338-1345.
31. Beiko J, et al. (2014) IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro-oncol 16(1):81-91.
32. Snyder LA, et al. (2014) The impact of extent of resection on malignant transformation of pure oligodendrogliomas. J Neurosurg 120(2):309-314.
33. Rohle D, et al. (2013) An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340(6132):626-630.
34. Capper D, et al. (2010) Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20(1):245-254.
35. Chi AS, et al. (2012) Prospective, high-throughput molecular profiling of human gliomas. J Neurooncol 110(1):89-98.
36. Dias-Santagata D, et al. (2011) BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: Diagnostic and therapeutic implications. PLoS ONE 6(3):e17948.
37. Hartmann C, et al. (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: A study of 1,010 diffuse gliomas. Acta Neuropathol 118(4):469-474.
38. Dias-Santagata D, et al. (2010) Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med 2(5):146-158.
39. Weller M, Wick W, von Deimling A (2011) Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas. Glia 59(8):1200-1204.
40. Eberlin LS, et al. (2011) Nondestructive, histologically compatible tissue imaging by desorption electrospray ionization mass spectrometry. ChemBioChem 12(14):2129-2132.
41. Navis AC, et al. (2013) Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: In situ detection of 2-HG and α-KG. Acta Neuropathol 1(18):10.1186/2051-5960-1-18.
42. Jolesz FA (2011) Intraoperative imaging in neurosurgery: Where will the future take us? Acta Neurochir Suppl (Wien) 109:21-25.
43. Yan H, et al. (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(8):765-773.
44. Leu S, et al. (2013) IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival. Neuro-oncol 15(4):469-479.
45. Kim BY, et al. (2014) Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testing. J Neurooncol 118(2):405-412.
46. Dunn GP, Andronesi OC, Cahill DP (2013) From genomics to the clinic: Biological and translational insights of mutant IDH1/2 in glioma. Neurosurg Focus 34(2):E2.
47. Sanai N, Martino J, Berger MS (2012) Morbidity profile following aggressive resection of parietal lobe gliomas. J Neurosurg 116(6):1182-1186.
48. Black PM, et al. (1997) Development and implementation of intraoperative magnetic resonance imaging and its neurosurgical applications. Neurosurgery 41(4):831-842, discussion 842-845.
49. Linehan WM, Srinivasan R, Schmidt LS (2010) The genetic basis of kidney cancer: A metabolic disease. Nat Rev Urol 7(5):277-285.
50. Ifa DR, Wu C, Ouyang Z, Cooks RG (2010) Desorption electrospray ionization and other ambient ionization methods: current progress and preview. Analyst (Lond) 135(4):669-681.
51. Nemes P, Vertes A (2012) Ambient mass spectrometry for in vivo local analysis and in situ molecular tissue imaging. TrAC -. Trends Analyt Chem 34:22-33.
52. Van Berkel GJ, Pasilis SP, Ovchinnikova O (2008) Established and emerging atmospheric pressure surface sampling/ionization techniques for mass spectrometry. J Mass Spectrom 43(9):1161-1180.
53. Liu J, Cooks RG, Ouyang Z (2011) Biological tissue diagnostics using needle biopsy and spray ionization mass spectrometry. Anal Chem 83(24):9221-9225.
54. Elhawary H, et al. (2011) Intraoperative real-time querying of white matter tracts during frameless stereotactic neuronavigation. Neurosurgery 68(2):506-516, discussion 516.